Compare FIRY & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIRY | PEPG |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.9M | 179.4M |
| IPO Year | 2020 | 2022 |
| Metric | FIRY | PEPG |
|---|---|---|
| Price | $12.45 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.19 |
| AVG Volume (30 Days) | 145.0K | ★ 792.8K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | N/A |
| Revenue This Year | $22.11 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.52 | N/A |
| 52 Week Low | $7.92 | $1.31 |
| 52 Week High | $14.12 | $7.80 |
| Indicator | FIRY | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 67.53 | 37.47 |
| Support Level | $9.31 | $1.60 |
| Resistance Level | $14.02 | $2.62 |
| Average True Range (ATR) | 0.78 | 0.17 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 67.32 | 18.90 |
Firy Inc, formerly Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. Its reportable segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube, among others. It generates the majority of its revenue from the Skillz segment. Geographically, the company derives its key revenue from the United States.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.